Mirodenafil is a phosphodiesterase 5 (PDE5) inhibitor.1 It increases penile intracavernosal pressure (ICP) in a rat model of diabetes induced by streptozotocin and in a rat model of cavernosal nerve injury when administered at doses of 1 and 10 mg/kg, respectively.1,2 Mirodenafil (4 mg/kg per day) decreases bladder wall submucosal fibrosis and degeneration in a rat model of chronic bladder ischemia.3 It also decreases bladder overactivity in a female rat model of partial bladder outlet obstruction.4
1.Park, K., Cho, S.Y., and Kim, S.W.Erectile response to type 5 phosphodiesterase inhibitor could be preserved with the addition of simvastatin to conventional insulin treatment in rat model of diabetesInt. J. Androl.34(5 Pt 2)e468-e474(2011) 2.Kim, H., Sohn, D.W., Kim, S.D., et al.The effect of mirodenafil on the penile erection and corpus cavernosum in the rat model of cavernosal nerve injuryInt. J. Impot. Res.22(5)291-297(2010) 3.Choi, H., Bae, J.H., Shim, J.S., et al.Mirodenafil prevents bladder dysfunction induced by chronic bladder ischemia in ratsInt. Neurourol. J.19(1)19-26(2015) 4.Kang, J.Y., Kim, E.K., and Kim, K.M.Effects of mirodenafil, a phosphodiesterase-5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model: Physiological and immunohistochemical aspectsKorean J. Urol.54(5)339-344(2013)